

EFFECTIVENESS AND SAFETY OF TOFACITINIB IN PATIENTS WITH CHRONIC ANTI-TNF REFRACTORY ULCERATIVE PROCTITIS: A MULTICENTER COHORT STUDY FROM THE GETAID

Matthieu Uzzan

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A retrospective multicenter study of 35 patients with anti-TNF refractory ulcerative proctitis found that tofacitinib achieved steroid-free clinical remission in 42.8% at induction and 39.4% at one year.

KEY POINTS

- Among 35 patients with chronic anti-TNF refractory ulcerative proctitis who had received a median of 2 prior biologic lines, 42.8% achieved steroid-free clinical remission at induction (weeks 8-14) and 60% achieved clinical response.
- At one year, steroid-free clinical remission and clinical response rates were 39.4% and 45.5%, respectively, with treatment persistence of 50.4%.
- Higher baseline partial Mayo score was the only factor independently associated with lower likelihood of achieving steroid-free remission at induction (adjusted OR 0.56 per one-unit increase).
- Five adverse events (14.3%) were reported including one septic shock requiring treatment withdrawal, one herpes zoster, and infections; no major cardiovascular events or deaths occurred.
- This multicenter GETAID study represents the largest real-world evidence for tofacitinib in ulcerative proctitis, a disease extent historically excluded from major UC trials.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/c7de4286-743b-11ee-a4f8-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.